APOLLOMICS, INC.

Other languages Apollomics, Inc.

Equities

APLM

KYG0411D1079

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-30 EDT			5-day change	1st Jan Change
0.3068 ^USD	+2.95%		+15.77%	-68.21%

05-08	Apollomics, Inc. Appoints Robert Lin to the Board of Directors	CI
05-08	Apollomics, Inc. announced that it has received $5.75 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apollomics, Inc. Appoints Robert Lin to the Board of Directors	05-08
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene	04-25
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer	04-05
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Apollomics Gets Nasdaq Noncompliance Notice	01-19
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	01-03
Top Premarket Gainers	11-27
Apollomics Announces Two New Cohorts in Global Phase 2 Sparta Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with Met Dysregulation	23-10-31
Sector Update: Health Care Stocks Slip in Late Afternoon	23-10-27
Sector Update: Health Care	23-10-27
Apollomics Shares Soar on Experimental Drug's Efficacy in Brain Tumor Patient	23-10-27
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast	23-10-27
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports	23-10-27
Top Premarket Gainers	23-10-27
Apollomics Inc. Announces Report of Activity of Vebrelinib in Glioblastoma Multiforme with PTPRZ-MET Fusion	23-10-26
Apollomics Inc. Announces Efficacy of Vebrelinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate of 75%	23-10-23
Apollomics, Inc. Announces Presentations of Vebreltinib Data at ESMO 2023	23-10-16
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer